Percentage of patients receiving care | |||
---|---|---|---|
Care indicator | All | Males | Females |
All (n = 4931) | 4931 (100%) | 2411 (48.9%) | 2520 (51.1%) |
Lipid profile | 3968 (78.9%) | 1977 (80.3%) | 1991 (77.4%) |
Waist circumference | 518 (10.3%) | 279 (11.3%) | 239 (9.3%) |
Dietician/weight loss program referral | 931 (18.5%) | 449 (18.2%) | 482 (18.8%) |
Smoking status recorded | 4805 (95.5%) | 2346 (95.4%) | 2459 (95.7%) |
2 Blood pressure measures | 3745 (74.1%) | 1778 (72.2%) | 1967 (76.5%) |
High-Risk for CVD (n = 1143) | 1143 (100%) | 507 (44.4%) | 636 (55.6%) |
Lipid profile | 904 (79.1%) | 408 (80.5%) | 496 (78.0%) |
Waist circumference measure | 85 (7.4%) | 49 (9.7%) | 36 (5.7%) |
Dietician/weight loss program referral | 142 (12.4%) | 60 (11.8%) | 82 (12.9%) |
Smoking status recorded | 1109 (97.0%) | 487 (96.0%) | 622 (97.8%) |
2 Blood pressure measures | 811 (100%) | 351 (69.2%) | 460 (72.3%) |
Coronary Artery Disease (n = 1502) | 1502 (100%) | 931 (62.0%) | 571 (22.4%) |
Fasting blood glucose | 1197 (79.7%) | 749 (80.5%) | 448 (78.5%) |
Medication (ACE, Angiotensin receptor blocker, beta blocker) | 1339 (89.2%) | 830 (89.2%) | 509 (89.2%) |
ASA | 1156 (77.0%) | 725 (77.8%) | 431 (75.5%) |
Peripheral Vascular Disease (n = 311) | 311 (100%) | 191 (61.4%) | 120 (38.6%) |
Fasting blood glucose | 244 (78.5%) | 154 (80.6%) | 90 (75.0%) |
ACE inhibitor and/or Angiotensin receptor blocker | 182 (58.5%) | 110 (57.6%) | 72 (60.0%) |
Lipid lowering medication | 232 (74.6%) | 147 (76.9%) | 85 (70.8%) |
ASA | 238 (76.5%) | 147 (77.0%) | 91 (75.8%) |
Stroke (n = 627) | 627 (100%) | 293 (46.7%) | 334 (53.3%) |
Fasting blood glucose | 474 (76.6%) | 225 (77.8%) | 249 (75.5%) |
ASA | 493 (79.6%) | 231 (79.9%) | 262 (79.4%) |
If stroke within past year (n = 69) | 69 (100%) | 32 (48.4%) | 37 (53.6%) |
Echo cardiogram | 36 (52.2%) | 15 (46.9%) | 21 (56.8%) |
Carotid doppler | 46 (66.7%) | 20 (62.5%) | 26 (70.3%) |
CT head scan | 51 (73.4%) | 24 (75.0%) | 27 (73.0%) |
EKG | 38 (55.1%) | 17 (53.1%) | 21 (56.8%) |
Diabetes (n = 2343) | 2343 (100%) | 1111 (47.4%) | 1232 (52.6%) |
Two HbA1c tests | 1275 (54.4%) | 622 (56.0%) | 653 (53.0%) |
Glycemic control medication | 1882 (80.3%) | 896 (80.7%) | 986 (80.0%) |
ACR | 1327 (56.1%) | 655 (58.5%) | 672 (54.0%) |
eGFR | 1959 (83.6%) | 934 (84.1%) | 1025 (83.2%) |
Chronic Kidney Disease (n = 923) | 923 (100%) | 406 (44.0%) | 517 (56.0%) |
ACR | 488 (52.9%) | 233 (57.4%) | 255 (49.3%) |
Dyslipidemia † (n = 4207) | 4207 (100%) | 2124 (50.5%) | 2083 (49.5%) |
Lipid profile | 3534 (83.2%) | 1799 (83.8%) | 1735 (82.6%) |
Lipid lowering medication | 3879 (91.4%) | 1993 (92.9%) | 1886 (89.8%) |
Hypertension ‡ (n = 3857) | 3857 (100%) | 1827 (47.4%) | 2030 (52.6%) |
Two blood pressure readings | 3083 (79.2%) | 1407 (77.1%) | 1649 (81.2%) |
Anti-Hypertensive medication | 3627 (94.0%) | 1713 (93.8%) | 1914 (94.3%) |
Smoking (n = 1076) | 1076 (100%) | 557 (51.8%) | 519 (48.2%) |
Smoking cessation counselling | 567 (52.7%) | 294 (52.8%) | 273 (52.6%) |
Smoking cessation program | 86 (8.0%) | 46 (8.3%) | 40 (7.7%) |
Smoking cessation drug | 249 (23.0%) | 128 (23.0%) | 121 (23.3%) |